Should we treat hypercholesterolaemia in patients over 65?
作者信息
Oliver M F
出版信息
Heart. 1997 Jun;77(6):491-2. doi: 10.1136/hrt.77.6.491.
Abstract
摘要
相似文献
1
Should we treat hypercholesterolaemia in patients over 65?我们应该治疗65岁以上患者的高胆固醇血症吗？
Heart. 1997 Jun;77(6):491-2. doi: 10.1136/hrt.77.6.491.
2
Getting tough with cholesterol.
Harv Heart Lett. 1998 Feb;8(6):1-4.
3
Cholesterol and coronary heart disease: screening and treatment.胆固醇与冠心病：筛查与治疗
Qual Health Care. 1998 Dec;7(4):232-9. doi: 10.1136/qshc.7.4.232.
4
Treatment of hypercholesterolemia in patients with known coronary artery disease.
Heart Dis Stroke. 1993 Sep-Oct;2(5):373-6.
5
[Hypercholesterolemia: to treat or not to treat? That is the question].[高胆固醇血症：治疗还是不治疗？这是个问题]
Rev Med Brux. 1994 May-Jun;15(3):124-31.
6
[Benefits and costs of early detection and treatment of hypercholesterolemia].[高胆固醇血症早期检测与治疗的益处及成本]
Z Kardiol. 1994;83 Suppl 6:163-7.
7
The potential role of soluble fibre in the treatment of hypercholesterolaemia.可溶性纤维在高胆固醇血症治疗中的潜在作用。
Postgrad Med J. 1998 Jul;74(873):391-4. doi: 10.1136/pgmj.74.873.391.
8
Addressing the spectrum of hypercholesterolemia.
Hosp Pract (1995). 1996 Jun 15;31(6):43-8, 53-5, 59; discussion 60.
9
Consensus conference. Lowering blood cholesterol to prevent heart disease.共识会议。降低血液胆固醇以预防心脏病。
JAMA. 1985 Apr 12;253(14):2080-6.
本文引用的文献
1
The low fat/low cholesterol diet is ineffective.低脂/低胆固醇饮食无效。
Eur Heart J. 1997 Jan;18(1):18-22. doi: 10.1093/oxfordjournals.eurheartj.a015111.
2
Lipid-lowering for prevention of coronary heart disease: what policy now?降低血脂以预防冠心病：现在该采取什么政策？
Clin Sci (Lond). 1996 Oct;91(4):399-413. doi: 10.1042/cs0910399.
3
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.普伐他汀对胆固醇水平正常的心肌梗死患者冠状动脉事件的影响。胆固醇与再发事件试验研究人员。
N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401.
4
Retardation and arrest of progression or regression of coronary artery disease: a review.冠状动脉疾病进展的延缓、停滞或逆转：综述
Prog Cardiovasc Dis. 1993 May-Jun;35(6):435-54. doi: 10.1016/0033-0620(93)90028-c.
5
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.采用系列定量动脉造影术评估HMG-CoA还原酶抑制剂单一疗法对冠状动脉粥样硬化进展的影响。加拿大冠状动脉粥样硬化干预试验。
Circulation. 1994 Mar;89(3):959-68. doi: 10.1161/01.cir.89.3.959.
6
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
N Engl J Med. 1995 Feb 23;332(8):481-7. doi: 10.1056/NEJM199502233320801.
7
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).普伐他汀降低血脂对血清胆固醇水平正常至中度升高的有症状男性冠心病进展和逆转的影响。回归生长评估他汀研究（REGRESS）。
Circulation. 1995 May 15;91(10):2528-40. doi: 10.1161/01.cir.91.10.2528.
8
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.普伐他汀预防高胆固醇血症男性冠心病。苏格兰西部冠心病预防研究组。
N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001.
Zotero 插件